Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate ADARx Pharmaceuticals, Inc. before investing.
In this article, we go over a few key elements for understanding ADARx Pharmaceuticals, Inc.’s stock price such as:
- ADARx Pharmaceuticals, Inc.’s current stock price and volume
- Why ADARx Pharmaceuticals, Inc.’s stock price changed recently
- Upgrades and downgrades for ADRX from analysts
- ADRX’s stock price momentum as measured by its relative strength
About ADARx Pharmaceuticals, Inc. (ADRX)
Before we jump into ADARx Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer’s disease. The company was incorporated in 2019 and is based in San Diego, California.
Want to learn more about ADARx Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about ADARx Pharmaceuticals, Inc..
ADARx Pharmaceuticals, Inc.’s Stock Price as of Market Close
As of November 20, 2026, 4:00 PM, CST, ADARx Pharmaceuticals, Inc.’s stock price was $12.790.
ADARx Pharmaceuticals, Inc. is down 9.68% from its previous closing price of $14.160.
During the last market session, ADARx Pharmaceuticals, Inc.’s stock traded between $12.630 and $14.870. Currently, there are approximately 16.13 million shares outstanding for ADARx Pharmaceuticals, Inc..
ADARx Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.
ADARx Pharmaceuticals, Inc. Stock Price History
ADARx Pharmaceuticals, Inc.’s (ADRX) price is currently down 24.76% so far this month.
During the month of November, ADARx Pharmaceuticals, Inc.’s stock price has reached a high of $17.030 and a low of $12.500.
Over the last year, ADARx Pharmaceuticals, Inc. has hit prices as high as $23.210 and as low as $12.500.
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions
What Caused ADARx Pharmaceuticals, Inc. Stock’s Price to Dip?
Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?
When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 20, 2026, there were analysts who downgraded ADARx Pharmaceuticals, Inc.’s stock and analysts who upgraded over the last month.
Additionally, you'll want to evaluate ADARx Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on ADARx Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.
ADARx Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.
Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.
Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about ADARx Pharmaceuticals, Inc. (ADRX) by visiting AAII Stock Evaluator.
Relative Price Strength of ADARx Pharmaceuticals, Inc.
Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.
For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.
As of November 20, 2026, ADARx Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.
Want to learn more about how ADARx Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.
ADARx Pharmaceuticals, Inc. Stock Price: Bottom Line
As of November 20, 2026, ADARx Pharmaceuticals, Inc.’s stock price is $12.790, which is down 9.68% from its previous closing price.
AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like ADARx Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.
Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.
Included With AAII Platinum
at only 6.9%
Gain Since Inception. Data as of 12/31/2024.
769.3% Stock Superstars Portfolio Total Return Since Inception
U.S. Index ETF (IYY)
SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.
FREE REPORT
BECOME A MEMBER FOR ONLY $2
Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.